Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing: earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures gives cross-border investors faster access to Tokyo-listed disclosures.
This corporate disclosure from MediciNova, Inc. was processed by Pulse News Wire on May 15, 2026. It represents a primary source document for Japanese Earnings sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
TOKYO, May 15 (Pulse News Wire) – Medicinova, Inc. (4875.T) reported consolidated results for Q1 FY2026 (ending December 2026). Revenue was ¥190 billion. operating profit was ¥2,835,806 million. net pr
View all MediciNova, Inc. disclosures →
TOKYO, May 15 (Pulse News Wire) – Medicinova, Inc. (4875.T) reported consolidated results for Q1 FY2026 (ending December 2026).
Revenue was ¥190 billion. operating profit was ¥2,835,806 million.
Net profit was ¥2,586,258 million.
Financial results — FY2026/12 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥186,984M | +2835806.0% |
| Operating profit | ¥2,586,258M | +2586258.0% |
| Net profit | n/a | n/a |
Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.